Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
62,130,557
-
Total 13F shares
-
19,762,209
-
Share change
-
+269,750
-
Total reported value
-
$26,479,807
-
Price per share
-
$1.34
-
Number of holders
-
31
-
Value change
-
-$1,331,635
-
Number of buys
-
14
-
Number of sells
-
13
Institutional Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) as of Q4 2022
As of 31 Dec 2022,
Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,762,209 shares.
The largest 10 holders included
TANG CAPITAL MANAGEMENT LLC, Laurion Capital Management LP, BVF INC/IL, CITADEL ADVISORS LLC, Newtyn Management, LLC, BARCLAYS PLC, VANGUARD GROUP INC, ORBIMED ADVISORS LLC, HHLR ADVISORS, LTD., and Tekla Capital Management LLC.
This page lists
31
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.